SynthesisBMC anesthesiology2023
Postoperative pulmonary complications after sugammadex reversal of neuromuscular blockade: a systematic review and meta-analysis with trial sequential analysis.
Synthesis in BMC anesthesiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Sugammadex and intraocular pressure: systematic review with meta-analysis and trial sequential analysis.BMC anesthesiology · 2026Pooled it
- Sugammadex versus no pharmacological reversal under quantitative neuromuscular monitoring: a propensity score-matched analysis of postoperative pulmonary complications.Journal of anesthesia · 2026Article
- Impact of Sugammadex on Clinical and Patient-Centered Outcomes: Beyond Neuromuscular Recovery.Journal of clinical medicine · 2026Review
- Comparison of kinemyography and electromyography during onset of and recovery from non-depolarising neuromuscular blockade: prospective observational study.Anaesthesiology intensive therapy · 2026Observational
- Current recommendations for preventing residual neuromuscular blockade.Anesthesia and pain medicine · 2026Review
- Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade and Association with Postoperative Atelectasis After Video-Assisted Thoracoscopic Surgery: A Propensity Score-Matched Cohort Study.Drug design, development and therapy · 2026Article
- In-depth exploration of sugammadex and novel neuromuscular blockade antagonists: a narrative review.Frontiers in pharmacology · 2026Review
- Sugammadex and Postoperative Respiratory Failure in Head and Neck Surgery: A Cohort Study.Drug design, development and therapy · 2026Article
- Article
- Ventilation strategies and risk factors for intraoperative respiratory critical events and postoperative pulmonary complications in neonates and small infants: a secondary analysis of the NECTARINE cohortBritish journal of anaesthesia · 2025Observational
- Effect of sugammadex on the prevention of postoperative lung atelectasis in patients undergoing metabolic and bariatric surgery: a retrospective study.Obesity surgery · 2025Article
- Sugammadex versus cholinesterase inhibitors to antagonize respiratory dysfunction after neuromuscular blockade in patients undergoing pulmonary surgery: a systematic review and meta-analysis.Perioperative medicine (London, England) · 2025Review
- Sugammadex for Neuromuscular Blockade Reversal: A Narrative Review.Journal of clinical medicine · 2025Review
- Risk of postoperative urinary retention after sugammadex use in laparoscopic hernia repair: A matched cohort study of 23,444 cases.PloS one · 2025Article
- Residual Neuromuscular Block Remains a Safety Concern for Perioperative Healthcare Professionals: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Benefits and quick adoption of the use of Sugammadex in a busy practice setting.International journal of physiology, pathophysiology and pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSugammadex has been reported to lower the incidence of postoperative residual neuromuscular blockade. Despite the advantages, until recently the effects of sugammadex on postoperative pulmonary complications (PPCs) were controversial. We conducted a systematic review and meta-analysis to determine whether reversal with sugammadex was associated with a lower risk of PPCs compared with neostigmine.
methodsPubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from inception to May 2022. Randomized controlled trials (RCTs) and observational studies comparing PPCs in patients receiving sugammadex or neostigmine as reversal agent at the end of surgery were included. The primary outcomes focused on PPCs including desaturation, pneumonia, atelectasis, noninvasive ventilation (NIV) and reintubation. Trial sequential analysis was performed on the primary outcomes to confirm whether firm evidence was reached.
resultsMeta-analysis of included studies showed that the rate of desaturation (43.2% vs 45.0%, RR = 0.82; 95% CI 0.63 to 1.05; p = 0.11) were comparable between the two groups. When looking at other primary outcomes, significantly lower risk of pneumonia (1.37% vs 2.45%, RR = 0.65; 95% CI 0.49 to 0.85; p = 0.002), atelectasis (24.6% vs 30.4%, RR = 0.64; 95% CI 0.42 to 0.98; p = 0.04), NIV (1.37% vs 2.33%, RR = 0.65; 95% CI 0.43 to 0.98; p = 0.04) and reintubation (0.99% vs 1.65%, RR = 0.62; 95% CI 0.43 to 0.91; p = 0.01) in the sugammadex group were detected compared with the neostigmine group.
conclusionsWe concluded that sugammadex is more effective at reducing the incidence of PPCs including pneumonia, atelectasis, NIV and reintubation compared with neostigmine. Further evidence, preferably from RCTs, is required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.